About Polyglutamylase complex subunit TTLL1
Polyglutamylase complex subunit TTLL1 (TTLL1) is a protein
from Homo sapiens identified by UniProt accession
O95922, 423 residues long.
MolForge cross-references it against 0 known binders and
132 disease associations.
Target properties
| Protein name | Polyglutamylase complex subunit TTLL1 |
| UniProt accession | O95922 |
| Gene | TTLL1 |
| Organism | Homo sapiens |
| Length | 423 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (132)
Diseases linked to this target (Open Targets).
- urate measurement · score 0.31
- bone density · score 0.31
- platelet component distribution width · score 0.31
- primary ovarian insufficiency · score 0.12
- azoospermia · score 0.09
- male infertility with teratozoospermia due to single gene mutation · score 0.07
- spermatogenic failure 65 · score 0.07
- prostate carcinoma · score 0.07
- spermatogenic failure 56 · score 0.07
- spermatogenic failure 51 · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95922-F1 | alphafold | PREDICTED | 85.38 | — |
Amino-acid sequence (423 residues)
MAGKVKWVTD IEKSVLINNF EKRGWVQVTE NEDWNFYWMS VQTIRNVFSV EAGYRLSDDQ IVNHFPNHYE LTRKDLMVKN IKRYRKELEK EGSPLAEKDE NGKYLYLDFV PVTYMLPADY NLFVEEFRKS PSSTWIMKPC GKAQGKGIFL INKLSQIKKW SRDSKTSSFV SQSNKEAYVI SLYINNPLLI GGRKFDLRLY VLVSTYRPLR CYMYKLGFCR FCTVKYTPST SELDNMFVHL TNVAIQKHGE DYNHIHGGKW TVSNLRLYLE STRGKEVTSK LFDEIHWIIV QSLKAVAPVM NNDKHCFECY GYDIIIDDKL KPWLIEVNAS PSLTSSTAND RILKYNLIND TLNIAVPNGE IPDCKWNKSP PKEVLGNYEI LYDEELAQGD GADRELRSRQ GQSLGPRAGR SRDSGRAVLT TWK
Explore Polyglutamylase complex subunit TTLL1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets